Dr. Tushar Shah - 10 Nov 2021 Form 4 Insider Report for Liquidia Corp (LQDA)

Role
CMO and Head of R&D
Signature
/s/ Russell Schundler, as attorney-in-fact for Dr. Tushar Shah
Issuer symbol
LQDA
Transactions as of
10 Nov 2021
Net transactions value
-$60,661
Form type
4
Filing time
12 Nov 2021, 20:03:49 UTC
Previous filing
23 Jul 2021
Next filing
19 Jan 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LQDA Common Stock Options Exercise +51,250 51,250 10 Nov 2021 Direct F1
transaction LQDA Common Stock Tax liability $2,457 -487 -0.95% $5.04 50,763 12 Nov 2021 Direct
transaction LQDA Common Stock Tax liability $58,204 -11,882 -23% $4.90 38,881 12 Nov 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LQDA Performance Stock Units Award $0 -51,250 -100% $0.000000* 0 10 Nov 2021 Common Stock 51,250 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each performance stock unit (PSU) converts into one share of common stock of the Issuer.
F2 On January 19, 2021, the reporting person was granted 51,250 PSUs, vesting in full upon tentative approval by the U.S. Food and Drug Administration of the New Drug Application for LIQ861.

Remarks:

Exhibit 24 - Power of Attorney